Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
ZAI LAB Plunges ~13% on Heavy Trading as Amgen's Bemarituzumab Final Analysis Shows Weaker Survival Benefit
Recommend 5 Positive 9 Negative 5 |
||||
|
||||
|
ZAI LAB (09688.HK) opened nearly 7% lower this morning (4th) and once sank to around a three-month low of HKD22.64. It last traded at HKD22.8, down 12.91%, with a trading volume surging to 34.608 million shares and a turnover of HKD808 million. According to Amgen (AMGN.US, ZAI LAB's partner and study sponsor, the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed. At the final analysis, the magnitude of the previously observed survival benefit has attenuated. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
